Published in Anticancer Drugs on October 01, 1997
Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer (2008) 1.35
Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors. Clin Cancer Res (2009) 1.08
Metastatic colorectal cancer-past, progress and future. World J Gastroenterol (2007) 1.04
Spectrum of cellular responses to pyriplatin, a monofunctional cationic antineoplastic platinum(II) compound, in human cancer cells. Mol Cancer Ther (2011) 1.03
Oxaliplatin with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (Modified FOLFOX 4) as first-line therapy for patients with metastatic colorectal cancer. Cancer Res Treat (2004) 1.02
Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Blood (2006) 1.02
Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies. Clin Colorectal Cancer (2011) 0.95
Chemoradiotherapy for colorectal cancer. Gut (2005) 0.93
Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil. Br J Cancer (2007) 0.93
Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. Br J Cancer (2002) 0.92
Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients. Br J Cancer (2005) 0.90
First-line chemotherapy for mCRC—a review and evidence-based algorithm. Nat Rev Clin Oncol (2015) 0.90
Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer. Br J Cancer (2004) 0.90
Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity. Br J Cancer (2002) 0.89
Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience. Int J Clin Oncol (2007) 0.86
Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells. Br J Cancer (2007) 0.85
Efficacy of a continuous venous infusion of fluorouracil and daily divided dose cisplatin as adjuvant therapy in resectable colorectal cancer: a prospective randomized trial. Surg Today (2008) 0.85
Evolution of nonsurgical therapy for colorectal cancer. Nat Clin Pract Gastroenterol Hepatol (2009) 0.84
A ceramic-based anticancer drug delivery system to treat breast cancer. J Mater Sci Mater Med (2010) 0.83
Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer. Br J Cancer (2005) 0.81
A phase I trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases from colorectal cancer. Ann Surg Oncol (2013) 0.80
Phase II clinical trial of advanced and metastatic gastric cancer based on continuous infusion of 5-fluorouracil combined with epirubicin and oxaliplatin. J Cancer Res Clin Oncol (2008) 0.80
Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells. Gastric Cancer (2012) 0.80
Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines. Br J Cancer (2001) 0.79
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine. Cancer Chemother Pharmacol (2008) 0.78
Preliminary investigation of intraperitoneal raltitrexed in patients with gastric cancer. World J Surg Oncol (2014) 0.77
Feasibility of Oxaliplatin, Leucovorin, and 5-Fluorouracil (FOLFOX-4) Chemotherapy in Heavily Pretreated Patients with Recurrent Epithelial Ovarian Cancer. Cancer Res Treat (2013) 0.76
Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer. BMC Cancer (2016) 0.76
Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer. Crit Rev Oncol Hematol (2016) 0.75
Oxaliplatin-induced neuropathy: a tale of two electrolytes. Support Care Cancer (2015) 0.75
A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: a Japanese experience. Surg Today (2011) 0.75
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol (2000) 16.83
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol (1997) 3.08
Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol (2004) 2.39
CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer (1999) 2.24
Molecular characterization of rifampin-resistant isolates of Mycobacterium tuberculosis from Hungary by DNA sequencing and the line probe assay. J Clin Microbiol (2001) 2.21
Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. Proc Natl Acad Sci U S A (1999) 2.19
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol (2002) 2.15
Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol (2004) 2.15
Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer (1997) 2.14
High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer (1977) 2.07
Common non-hormone binding component in non-transformed chick oviduct receptors of four steroid hormones. Nature (1984) 2.04
Precipitation of fluorouracil in elastomeric infusers with a polyisoprene reservoir and in polypropylene syringes with an elastomeric joint. Am J Health Syst Pharm (1997) 2.04
Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol (1998) 2.03
Evidence for a role of Rho-like GTPases and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in transforming growth factor beta-mediated signaling. J Biol Chem (1997) 2.00
Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. Ann Oncol (2013) 1.82
Cloning of a novel human Rac1b splice variant with increased expression in colorectal tumors. Oncogene (1999) 1.82
Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, rho-, and rac-dependent signaling pathways. FASEB J (2000) 1.75
High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol (1988) 1.74
Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer (1999) 1.72
Immortalization of mouse intestinal epithelial cells by the SV40-large T gene. Phenotypic and immune characterization of the MODE-K cell line. J Immunol Methods (1993) 1.72
Effect of attenuation correction on lesion detectability in FDG PET of breast cancer. J Nucl Med (1999) 1.70
Association of vitamin D deficiency with cognitive impairment in older women: cross-sectional study. Neurology (2009) 1.65
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol (1999) 1.64
Cell therapy with autologous tolerogenic dendritic cells induces allograft tolerance through interferon-gamma and epstein-barr virus-induced gene 3. Am J Transplant (2011) 1.60
Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res (1996) 1.59
Vitamin D and cognitive performance in adults: a systematic review. Eur J Neurol (2009) 1.51
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann Oncol (2004) 1.51
Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia (1998) 1.49
4-Methylpyrazole and hemodialysis in ethylene glycol poisoning. J Toxicol Clin Toxicol (1996) 1.49
Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration. J Bone Miner Res (1996) 1.48
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006. Ann Oncol (2007) 1.44
Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int J Cancer (1995) 1.43
Oestrogen receptors in chick oviduct. Characterization and subcellular distribution. Eur J Biochem (1975) 1.42
High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer (2001) 1.41
Characterization of a newly established human gastric cancer cell line HGT-1 bearing histamine H2-receptors. Cancer Res (1982) 1.40
Incorporation and distribution of strontium in bone. Bone (2001) 1.40
Similar cytogenetic abnormalities in two cases of plasma cell leukemia. Cancer Genet Cytogenet (1991) 1.40
Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol (1999) 1.40
Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol (2002) 1.39
[Moderate hyper-homocysteinemia and coronary involvement]. Presse Med (1996) 1.39
Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer J Sci Am (2006) 1.38
Oxaliplatin clinical activity: a review. Crit Rev Oncol Hematol (2000) 1.35
Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol (2001) 1.33
Opposing roles of netrin-1 and the dependence receptor DCC in cancer cell invasion, tumor growth and metastasis. Oncogene (2007) 1.32
Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol (1994) 1.31
Activation of int-1 and int-2 mammary oncogenes in hormone-dependent and -independent mammary tumors of GR mice. J Virol (1987) 1.29
Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. J Clin Oncol (2000) 1.29
Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol (2009) 1.29
Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity. J Clin Oncol (2001) 1.26
Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Intern Med (1988) 1.25
The evolution of mature teratoma from malignant testicular tumors. Cancer (1977) 1.24
Autocrine induction of invasion and metastasis by tumor-associated trypsin inhibitor in human colon cancer cells. Oncogene (2008) 1.24
The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer (1977) 1.24
Nuclear estrogen receptor of chick liver. Biochim Biophys Acta (1972) 1.22
Bile acids stimulate invasion and haptotaxis in human colorectal cancer cells through activation of multiple oncogenic signaling pathways. Oncogene (2002) 1.22
Fully automatic identification of AC and PC landmarks on brain MRI using scene analysis. IEEE Trans Med Imaging (1997) 1.20
Mucin gene expression in human embryonic and fetal intestine. Gut (1998) 1.19
Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol (1997) 1.18
The role of bile acids in carcinogenesis. Mutat Res (2001) 1.17
Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer (1977) 1.16
Evidence for the involvement of the Wnt 2 gene in human colorectal cancer. Oncogene (1996) 1.15
Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol (1996) 1.13
Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer (2008) 1.12
Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biol Cell (1995) 1.12
Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer. Eur J Cancer (2002) 1.12
Prognostic value of clinicopathological parameters in head and neck squamous cell carcinoma: a prospective analysis. Br J Cancer (1996) 1.11
Porcine peptide having N-terminal histidine and C-terminal isoleucine amide (PHI): vasoactive intestinal peptide (VIP) and secretin-like effects in different tissues from the rat. FEBS Lett (1980) 1.11
Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int J Cancer (2000) 1.11
cis-Platinum ototoxicity. Clin Toxicol (1978) 1.11
Deregulated expression of homeobox-containing genes, HOXB6, B8, C8, C9, and Cdx-1, in human colon cancer cell lines. Biochem Biophys Res Commun (2000) 1.10
Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. Eur J Cancer (1996) 1.10
Tamoxifen is a potent "pure" anti-oestrogen in chick oviduct. Nature (1977) 1.10
Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects. Int J Radiat Oncol Biol Phys (1995) 1.10
Protein kinase WNK2 inhibits cell proliferation by negatively modulating the activation of MEK1/ERK1/2. Oncogene (2007) 1.09
FDG PET detection of unknown primary tumors. J Nucl Med (2000) 1.08
Human polymorphonuclear neutrophils. Pharmacological characterization of histamine receptors mediating the elevation of cyclic AMP. Mol Pharmacol (1982) 1.08
A double competitive binding method of measuring oestradiol from menstrual cycle plasma with and without the prior purification of oestradiol. Acta Endocrinol (Copenh) (1971) 1.08
Human colorectal carcinogenesis is associated with deregulation of homeobox gene expression. Biochem Biophys Res Commun (1997) 1.08
Training and overtraining markers in selected sport events. Med Sci Sports Exerc (2000) 1.08
[Progressive myoclonic encephalopathy in dialysis patients. The role of the water used for haemodialysis (author's transl)]. Nouv Presse Med (1978) 1.08
Identification and characterization of surface receptors for histamine in the human promyelocytic leukemia cell line HL-60. Comparison with human peripheral neutrophils. Mol Pharmacol (1982) 1.08
Downregulation of the colon tumour-suppressor homeobox gene Cdx-2 by oncogenic ras. Oncogene (1999) 1.08
Effects of thyroparathyroidectomy on the distribution of bromine and iodine in rat tissues. Biol Trace Elem Res (1992) 1.07
[Chronic arsenicism]. Ann Dermatol Venereol (2001) 1.07
Induction of scattering and cellular invasion by trefoil peptides in src- and RhoA-transformed kidney and colonic epithelial cells. FASEB J (2001) 1.06
Expression of prolactin and growth hormone receptor genes and their isoforms in the gastrointestinal tract. Am J Physiol (1995) 1.06
CIS-Dichlorodiammineplatinum(II) in the treatment of epidermoid carcinoma of the head and neck. Cancer Treat Rep (1977) 1.06
Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann Oncol (2004) 1.06
An immunomodulatory role for follistatin-like 1 in heart allograft transplantation. Am J Transplant (2008) 1.05
Sequential bilateral germ cell tumors of the testis despite interval chemotherapy. J Urol (1979) 1.05
Factors influencing postoperative morbidity and mortality in patients treated with bleomycin. Br Med J (1978) 1.04
Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol (1998) 1.03
Induction of apoptosis by DPC4, a transcriptional factor regulated by transforming growth factor-beta through stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) signaling pathway. J Biol Chem (1997) 1.03
Extraskeletal mesenchymal chondrosarcoma: case report and review of the literature. J Clin Oncol (1985) 1.03
Progesterone receptors in the chick oviduct. Determination of the total concentration of binding sites in the cytosol and nuclear fraction and effect of progesterone on their distribution. Eur J Biochem (1977) 1.02
Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol (1998) 1.02
Dynamics of oestrogen-receptor distribution between the cytosol and nuclear fractions of immature rat uterus after oestradiol administration. Biochem J (1975) 1.02